Call(WhatsApp Us)
+8615360806100Email Us
cherry@laeyo.comSee the factory by live video walkthrough
Book an on-site factory visit in GuangzhouA viscosity result outside the approved specification on a face cream batch is a release blocker, not a paperwork nuisance. Viscosity drives how the cream fills, how the jar or pump performs, how the…
A viscosity result outside the approved specification on a face cream batch is a release blocker, not a paperwork nuisance. Viscosity drives how the cream fills, how the jar or pump performs, how the product spreads, and whether the texture still matches the sample the brand approved. When a batch fails the viscosity specification, the buyer-facing question is narrow and practical: what has to be closed, documented, and signed off before that batch can legally and commercially ship? This guide walks sourcing managers and brand owners through the sequence a manufacturer should follow — hold, dual investigation, impact assessment, rework risk review, and a controlled batch release decision — and tells you exactly which documents to request at each step.
Before an out-of-specification (OOS) investigation means anything, the specification has to be unambiguous. A viscosity limit written as “40,000–60,000 mPa·s” without a method is not a specification — it is an invitation to dispute. The approved spec for a face cream should define the test method ID, instrument and spindle, rotational speed, temperature, equilibration time, and sampling point (bulk vs. finished pack).
| Control item | What the spec should state | Frequency | Critical? |
|---|---|---|---|
| Appearance | Match against the controlled Golden sample (colour, gloss, uniformity) | Each batch | Yes |
| pH | SKU-defined range, defined dilution and temperature | Each batch | Yes |
| Viscosity | SKU-defined range + method ID, spindle, rpm, temperature, equilibration time | Each batch | Yes |
| Microbiology | Per target-market limits (e.g., US, EU, China differ) | Each batch | Yes |
| Packaging compatibility | Pump dispensing force, jar torque, label adhesion, fragrance–plastic interaction | Per SKU / on change | Yes |
If the result is outside the limit, it is an OOS and the batch is frozen. If the result is inside the limit but drifting toward the edge — for example a historical centre of 50,000 mPa·s against a 40,000–60,000 range, with the current batch at 41,500 — that is an out-of-trend (OOT) signal. It is not automatically escalated to OOS, but it still warrants a documented trend review, because the next batch may cross the lower limit. A manufacturer that only reacts to OOS and never charts trends is a manufacturer you will eventually have a recall conversation with.
The correct first action is a hold, not a retest. The batch, the retained samples, and any finished goods already packed from that bulk should be placed on hold while two investigations run in parallel:
Only after both investigations are documented should a retest be considered, and only under a pre-approved retest plan that states how many retests, on which sample (original or retained), by whom, and what happens if the retest also fails. Retesting until the number looks acceptable is not an investigation.
Thinning or thickening a failed cream back into specification is possible, but it is a formal, risk-assessed activity — not a production-floor adjustment. Before any rework or reprocessing is approved, the manufacturer should complete and document a risk assessment covering:
Ask directly: “Has QA approved this rework in writing, and does the approval reference the stability and micro assessments?” If the answer is no, the batch is not reworkable — it is a reject.
Batch release is a decision, not an automatic consequence of tests passing. For a face cream in any market, the release decision should be traceable to a defined input set:
Commercial pressure does not override a quality hold. If a sales deadline is cited as the reason a batch is being released, treat that as a warning sign, not a reassurance.
Send this list as-is. Every item has a deliverable attached to it, which is what makes the request answerable rather than negotiable.
| Phase | Buyer action | Manufacturer action | Evidence output |
|---|---|---|---|
| Day 0–1 | Confirm the hold in writing; stop any shipment | Freeze batch, retain samples, and affected finished goods | Hold notice with batch ID and scope |
| Day 1–3 | Request the investigation plan and retest plan | Run laboratory investigation; verify method and instrument | Lab investigation record, calibration records |
| Day 1–5 | Ask which raw material lots and lines are implicated | Run manufacturing investigation and impact-lot review | Manufacturing investigation report, impact-lot list |
| Day 3–7 | Decide: reject, rework, or continue investigation | Complete rework risk assessment if rework is proposed | Signed risk assessment with stability/micro/performance sections |
| Week 2–4 | Review bridging data before agreeing to release | Stability and micro checks on reworked bulk; packaging re-check | Updated stability and micro results, packaging compatibility report |
| On closure | Confirm documentation is complete before payment or shipment | Issue final disposition and release record | COA, batch release record, CAPA, retained sample confirmation |
Root cause: retesting used as a substitute for root-cause analysis. Prevention: require an approved retest plan and a written investigation before any retest is accepted. Request: the lab investigation record and the retest plan approval.
Root cause: packaging compatibility was validated at the target viscosity centre, and the batch sits at the lower edge of the range, changing flow behaviour through the pump. Prevention: require dispensing-force and torque testing across the full viscosity range, not just at the midpoint. Request: a packaging compatibility report linking bulk viscosity to pump output and jar torque.
Root cause: documentation control failure — the COA references an older specification, or the release record omits an open OOS. Prevention: require the release record to reference result IDs, deviation IDs, and the current spec version. Request: the signed release record plus the specification version history.
Root cause: rework approved without a stability assessment. Prevention: no rework without a QA-approved risk assessment that includes accelerated stability. Request: the stability protocol and results for the reworked bulk.
Root cause: a downward drift was visible in trend data but never reviewed as an OOT signal. Prevention: require trend charts and documented OOT reviews, not just pass/fail reporting. Request: the last 10–20 batch trend chart and any OOT review records.
Root cause: retain sample policy not applied per batch, or storage conditions not controlled. Prevention: make retain sample confirmation a release prerequisite. Request: the retain sample log with storage conditions and formula version.
No. An OOT result is still within specification, so it does not automatically escalate to OOS. It does, however, trigger a documented trend review to find the cause of the drift — such as raw material degradation or microbial activity — and to assess whether the product will remain reliable across its shelf life.
Only through a formally approved rework or reprocessing route. That requires a risk assessment covering stability, microbiological, and performance impact, and it requires quality approval before the adjustment is made. Without that, the batch should be rejected.
Through a combination of per-batch release parameters (appearance, pH, viscosity, micro), process proxies (raw material identity, active dosage, temperature, shear, hold time), comparison against a controlled Golden sample, and periodic performance verification. Revalidation is triggered by formula, process, or raw material changes.
The OOS investigation report, because it shows whether the manufacturer investigated both the laboratory and the manufacturing process, and whether the conclusion is supported by data or by convenience.
Informational only, not legal advice. Market-specific labelling, registration, and claims requirements should be confirmed with your regulatory specialist for each destination market.
Need a manufacturing partner who will hand over the investigation record, trend chart, and release documentation without being asked twice? Request a Quote and include your target market, SKU list and formats, positioning, packaging direction, and timeline so the response comes back with real lead times rather than a generic reply.